目的 研究注射用头孢替坦二钠在中国健康人体内的药动学。方法 12名健康志愿者,男女各半,平行法分别静脉滴注单剂量注射用头孢替坦二钠0.50、1.00和2.00 g,采用离子对反相色谱法测定头孢替坦二钠的经时血药浓度和尿药浓度,使用DAS软件估算药动学参数。结果 单剂量静脉滴注注射用头孢替坦二钠0.50、1.00和2.00 g的主要药动学参数:ρmax分别为(67.93±9.04),(151.7±12.08)和(263.8±30.35) mgL-1;AUC0-∞分别为(229.0±18.35),(459.2±30.23)和(889.6±94.35) mghL-1;而t1/2和MRT均不随剂量改变;0～24 h的尿药累积排泄率分别为(51.10±11.05)%,(62.29±16.36)%和(66.12±16.78)%。结论 建立的头孢替坦二钠血浆和尿液样品离子对反相色谱测定法专属灵敏,适于人体药动学研究。0.50~2.00 g内单次静脉滴注注射用头孢替坦二钠,在中国人体内呈线性药动学特征,男女无差异。
Abstract
OBJECTIVE To investigate the pharmacokinetics of cefotetan for injection in Chinese healthy volunteers. METHODS Twelve volunteers (6 men and 6 women) were intravenously infused with single dose of 0.50、1.00 and 2.00 g cefotetan for injection, respectively. The plasma and urine concentration of cefotetan was determined by an ion-pairing reversed-phase HPLC method. The pharmacokinetic parameters were calculated by DAS software. RESUTLS The main pharmacokinetic parameters found for 0.50、 1.00 and 2.00 g cefotetan for injection were as follows, respectively: ρmax(67.93±9.04), (151.7±12.08) and (263.8±30.35) mgL-1;AUC0-∞ (229.0±18.35),(459.2±30.23) and (889.6±94.35) mghL-1, while the t1/2 and MRT did not change obviously with the doses. The accumulative excretion rate of cefotetan through urine in 24 h was (51.10±11.05)%,(62.29±16.36)% and (66.12±16.78)%, respectively. CONCLUSION The established ion-pairing reversed-phase HPLC method is specific, sensitive and suitable for pharmacokinetic study of cefotetan in vivo. Linear pharmacokinetics is found for cefotetan in Chinese healthy volunteers after iv infusion in the dose range studied from 0.50 to 2.00 g without obvious gender differences.
关键词
头孢替坦二钠 /
药动学 /
离子对反相色谱法
{{custom_keyword}} /
Key words
cefotetan /
pharmacokinetics /
ion-pairing reversed-phase HPLC
{{custom_keyword}} /
中图分类号：
R969.1
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] CHAPMAN S J, OWEN J. Randomized trial of single-dose versus multiple-dose cefotetan for the postpartum treatment of intrapartum chorioamnionitis[J]. Am J Obstet Gynecol, 1997, 177(4):831-834.[2] MILSOM J W, SMITH D L, CORMAN M L, et al. Double-blind comparison of single-dose alatrofloxacin and cefotetan as prophylaxis of infection following elective colorectal surgery[J]. Am J Surg, 1998, 176(6):46-52.[3] QUINTILIANI R, NIGHTINGALE C H, STEVENS R C,et al. Comparative pharmacokinetics of cefotetan and cefoxitin in patients undergoing hysterectomies and colorectal operations[J]. Am J Surg, 1988, 155(5):67-70.[4] SHI S, LIU Y, LI Z, et al. Pharmacokinetics and tolerability of intravenous cefotetan disodium for injection in healthy Chinese volunteers:A randomized, open-label, single-and multiple-dose study[J]. Clin Ther, 2010, 32(10):1832-1841.[5] NAKAGAWA K, KOYAMA M, TACHIBANA A,et al. Pharmacokinetics of cefotetan (YM09330) in humans[J]. Antimicrob Agents Chemother, 1982, 22(6):935-941.[6] QIU F, HE X J, SUN Y X, et al. Pharmacokinetics of intravenous injection cefotetan in healthy volunteers[J]. Chin J Hosp Pharm(中国医院药学杂志),2012,32(24):1960-1964.[7] SU M, LI M, DI B, et al. Pharmacokinetic differences between the epimers of cefotetan disodium after single intravenous injection in healthy Chinese volunteers[J]. Eur J Drug Metab Pharmacokinet, 2011, 36(4):223-228.[8] YATES R A, ADAM H K, DONNELLY R J, et al. Pharmacokinetics and tolerance of single intravenous doses of cefotetan disodium in male caucasian volunteers[J]. J Antimicrob Chemother, 1983, 11(suppl A):185-191.[9] GUIBERT J, KITZIS M D, YVELIN C, et al. Pharmacokinetics of single intravenous and intramuscular doses of cefotetan in normal human volunteers[J]. J Antimicrob Chemother, 1983, 11(suppl A):201-206.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(1037 KB)
